ClinicalTrials.gg

Program

Oncolytic Virus M1-c6v1

Also written as “VRT106”, “VRT106 for injection” and “VRT106 in combination with camrelizumab and apatinib”.

Its studies are mostly in Diffuse Intrinsic Pontine Glioma · Glioblastoma, led by Guangzhou Virotech Pharmaceutical.

Furthest: phase 3, since May 8, 20266 company-led studies, 6 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou Virotech Pharmaceutical66 open or runningphase 3since May 8, 2026Sep 12, 2023Sep 2027phase 1 · NCT06368921

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2023First study: phase 1 study in Solid TumorFirst studyNCT06046742 · 12 planned · Japan
  2. Apr 9, 2024Phase 1 study in Solid TumorNCT06368921 · 30 planned · China
  3. Feb 10, 2025Phase 1 study in Solid TumorsNCT06826313 · 12 planned · China
  4. Jul 15, 2025Phase 2 study in GlioblastomaNCT07093814 · 42 planned · China
  5. May 8, 2026Phase 2 study in Diffuse Intrinsic Pontine GliomaNCT07589257 · 10 planned · China
  6. May 8, 2026Phase 3 study in HCCPhase 3 reachedNCT07589244 · 66 planned · China

Ahead

  1. Sep 2027Primary completion: phase 1 study in Solid TumorNCT06368921
  2. Jun 30, 2028Primary completion: phase 2 study in Diffuse Intrinsic Pontine GliomaNCT07589257
  3. Jun 30, 2028Primary completion: phase 1 study in Solid TumorNCT06046742
  4. Dec 30, 2028Primary completion: phase 1 study in Solid TumorsNCT06826313

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07589257Diffuse Intrinsic Pontine Glioma · China2RecruitingJun 30, 202810
NCT07589244HCC · China3RecruitingDec 31, 202866
NCT07093814Glioblastoma · China2RecruitingDec 31, 202842
NCT06826313Solid Tumors · China1RecruitingDec 30, 202812
NCT06368921Solid Tumor · China1RecruitingSep 202730
NCT06046742Solid Tumor · Japan1RecruitingJun 30, 202812

How it is read

Names in the registry

  • “VRT106”, 4 entries
  • “VRT106 for injection”, 1 entry
  • “VRT106 in combination with camrelizumab and apatinib”, 1 entry
  • “M1-c6v1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.